Lei Guiyu, Yang Siliu, Wu Lili, Yin Yue, Zhang Shu, Wang Guyan
Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Department of Anesthesiology, Beijing Dongcheng Maternal and Child Health Care Hospital, Beijing, 100007, China.
Heliyon. 2024 Mar 24;10(7):e28304. doi: 10.1016/j.heliyon.2024.e28304. eCollection 2024 Apr 15.
The aim of this study was to assess whether intravenous dexamethasone was noninferior to perineural dexamethasone as an adjuvant to ropivacaine for a combination of saphenous and sciatic nerve blocks in patients undergoing foot and ankle surgery.
This was a prospective, blinded, randomized noninferiority study. Seventy-five patients, aged 18-75 years, with an American Society of Anesthesiologists (ASA) physical status I-III who underwent foot and ankle surgery were involved. Patients scheduled for ultrasound-guided popliteal sciatic nerve block and saphenous nerve block were randomized to receive 0.375% ropivacaine with 7.5 mg of dexamethasone perineurally (Dex-PN), 10 mg of dexamethasone intravenously (Dex-IV) or neither (Placebo). The primary outcome was the duration of analgesia. The major secondary outcomes were the composite pain intensity and opioid consumption score at 0-48 h intervals after anesthesia.
The mean analgesic duration was 26.2 h in the Dex-IV group and 27.9 h in the Dex-PN group (duration difference, -1.7; 95% CI, -3.8 to 0.43; P = 0.117), and both durations were significantly longer than that in the placebo group (17.6 h, P < 0.001). Conditions for establishing non-inferiority were met.
Our findings indicate that a single 10-mg intravenous dose of dexamethasone was noninferior to the combined dose of ropivacaine plus deaxmethasone in terms of duration of analgesia for foot and ankle surgery.
本研究旨在评估在足踝手术患者中,作为罗哌卡因辅助用药时,静脉注射地塞米松与神经周围注射地塞米松用于隐神经和坐骨神经联合阻滞是否非劣效。
这是一项前瞻性、双盲、随机非劣效性研究。纳入75例年龄在18 - 75岁、美国麻醉医师协会(ASA)身体状况分级为I - III级且接受足踝手术的患者。计划接受超声引导下腘窝坐骨神经阻滞和隐神经阻滞的患者被随机分为三组,分别接受每神经周围注射含7.5 mg地塞米松的0.375%罗哌卡因(Dex - PN组)、静脉注射10 mg地塞米松(Dex - IV组)或不接受任何干预(安慰剂组)。主要结局指标为镇痛持续时间。主要次要结局指标为麻醉后间隔0 - 48小时的综合疼痛强度和阿片类药物消耗评分。
Dex - IV组的平均镇痛持续时间为26.2小时,Dex - PN组为27.9小时(持续时间差异为 - 1.7;95%置信区间为 - 3.8至0.43;P = 0.117),两组的镇痛持续时间均显著长于安慰剂组(17.6小时,P < 0.001)。满足非劣效性判定条件。
我们的研究结果表明,对于足踝手术的镇痛持续时间而言,单次静脉注射10 mg地塞米松在非劣效于罗哌卡因加地塞米松联合用药。